The two sides of chromosomal instability: drivers and brakes in cancer
Top Cited Papers
Open Access
- 29 March 2024
- journal article
- review article
- Published by Springer Nature in Signal Transduction and Targeted Therapy
- Vol. 9 (1) , 1-30
Abstract
Chromosomal instability (CIN) is a hallmark of cancer and is associated with tumor cell malignancy. CIN triggers a chain reaction in cells leading to chromosomal abnormalities, including deviations from the normal chromosome number or structural changes in chromosomes. CIN arises from errors in DNA replication and chromosome segregation during cell division, leading to the formation of cells with abnormal number and/or structure of chromosomes. Errors in DNA replication result from abnormal replication licensing as well as replication stress, such as double-strand breaks and stalled replication forks; meanwhile, errors in chromosome segregation stem from defects in chromosome segregation machinery, including centrosome amplification, erroneous microtubule–kinetochore attachments, spindle assembly checkpoint, or defective sister chromatids cohesion. In normal cells, CIN is deleterious and is associated with DNA damage, proteotoxic stress, metabolic alteration, cell cycle arrest, and senescence. Paradoxically, despite these negative consequences, CIN is one of the hallmarks of cancer found in over 90% of solid tumors and in blood cancers. Furthermore, CIN could endow tumors with enhanced adaptation capabilities due to increased intratumor heterogeneity, thereby facilitating adaptive resistance to therapies; however, excessive CIN could induce tumor cells death, leading to the “just-right” model for CIN in tumors. Elucidating the complex nature of CIN is crucial for understanding the dynamics of tumorigenesis and for developing effective anti-tumor treatments. This review provides an overview of causes and consequences of CIN, as well as the paradox of CIN, a phenomenon that continues to perplex researchers. Finally, this review explores the potential of CIN-based anti-tumor therapy.Keywords
Funding Information
- National Natural Science Foundation of China (32070715, 32270778, 82173029, 82372655)
- Natural Science Foundation of Chongqing Municipality (CSTB2022NSCQ-MSX0612, CSTB2022NSCQ-MSX0611)
This publication has 675 references indexed in Scilit:
- Efficacy and Safety of Weekly Paclitaxel With or Without Oral Alisertib in Patients With Metastatic Breast CancerJAMA Network Open, 2021
- Alisertib in Combination With Weekly Paclitaxel in Patients With Advanced Breast Cancer or Recurrent Ovarian CancerJAMA Oncology, 2019
- A phase 1 study of AMG 900, an orally administered pan‐aurora kinase inhibitor, in adult patients with acute myeloid leukemiaAmerican Journal of Hematology, 2017
- Open‐label, multicenter, phase 1 study of alisertib (MLN8237), an aurora A kinase inhibitor, with docetaxel in patients with solid tumorsCancer, 2016
- Chromosomal instability portends superior response of rectal adenocarcinoma to chemoradiation therapyCancer, 2014
- An open‐label, single‐arm, phase 2 trial of the polo‐like kinase inhibitor volasertib (BI 6727) in patients with locally advanced or metastatic urothelial cancerCancer, 2013
- Stage I of a phase 2 study assessing the efficacy, safety, and tolerability of barasertib (AZD1152) versus low‐dose cytosine arabinoside in elderly patients with acute myeloid leukemiaCancer, 2013
- Micronuclei-associatedMYCamplification in the form of double minute chromosomes in acute myeloid leukemiaAmerican Journal of Hematology, 2013
- A phase 1 dose‐escalation study of ARRY‐520, a kinesin spindle protein inhibitor, in patients with advanced myeloid leukemiasCancer, 2011
- Clinical and genetic heterogeneity in patients with mosaic variegated aneuploidy: Delineation of clinical subtypesAmerican Journal of Medical Genetics Part A, 2008